219 related articles for article (PubMed ID: 36408685)
21. Additional Diagnostic Value of Growth Differentiation Factor-15 (GDF-15) to N-Terminal B-Type Natriuretic Peptide (NT-proBNP) in Patients with Different Stages of Heart Failure.
Li J; Cui Y; Huang A; Li Q; Jia W; Liu K; Qi X
Med Sci Monit; 2018 Jul; 24():4992-4999. PubMed ID: 30019695
[TBL] [Abstract][Full Text] [Related]
22. Association of Cardiac Biomarkers With the Kansas City Cardiomyopathy Questionnaire in Patients With Chronic Kidney Disease Without Heart Failure.
Tummalapalli SL; Zelnick LR; Andersen AH; Christenson RH; deFilippi CR; Deo R; Go AS; He J; Ky B; Lash JP; Seliger SL; Soliman EZ; Shlipak MG; Bansal N;
J Am Heart Assoc; 2020 Jul; 9(13):e014385. PubMed ID: 32578483
[TBL] [Abstract][Full Text] [Related]
23. Association of Multiple Biomarkers With Risk of All-Cause and Cause-Specific Mortality After Acute Coronary Syndromes: A Secondary Analysis of the PLATO Biomarker Study.
Lindholm D; James SK; Gabrysch K; Storey RF; Himmelmann A; Cannon CP; Mahaffey KW; Steg PG; Held C; Siegbahn A; Wallentin L
JAMA Cardiol; 2018 Dec; 3(12):1160-1166. PubMed ID: 30427997
[TBL] [Abstract][Full Text] [Related]
24. Variability of biomarkers in patients with chronic heart failure and healthy controls.
Meijers WC; van der Velde AR; Muller Kobold AC; Dijck-Brouwer J; Wu AH; Jaffe A; de Boer RA
Eur J Heart Fail; 2017 Mar; 19(3):357-365. PubMed ID: 27766733
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic performance and reference values of novel biomarkers of paediatric heart failure.
Hauser JA; Demyanets S; Rusai K; Goritschan C; Weber M; Panesar D; Rindler L; Taylor AM; Marculescu R; Burch M; Wojta J; Michel-Behnke I
Heart; 2016 Oct; 102(20):1633-9. PubMed ID: 27220692
[TBL] [Abstract][Full Text] [Related]
26. Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction.
Santhanakrishnan R; Chong JP; Ng TP; Ling LH; Sim D; Leong KT; Yeo PS; Ong HY; Jaufeerally F; Wong R; Chai P; Low AF; Richards AM; Lam CS
Eur J Heart Fail; 2012 Dec; 14(12):1338-47. PubMed ID: 22869458
[TBL] [Abstract][Full Text] [Related]
27. Growth Differentiation Factor 15 Provides Prognostic Information Superior to Established Cardiovascular and Inflammatory Biomarkers in Unselected Patients Hospitalized With COVID-19.
Myhre PL; Prebensen C; Strand H; Røysland R; Jonassen CM; Rangberg A; Sørensen V; Søvik S; Røsjø H; Svensson M; Berdal JE; Omland T
Circulation; 2020 Dec; 142(22):2128-2137. PubMed ID: 33058695
[TBL] [Abstract][Full Text] [Related]
28. Growth-differentiation factor-15 is a robust, independent predictor of 11-year mortality risk in community-dwelling older adults: the Rancho Bernardo Study.
Daniels LB; Clopton P; Laughlin GA; Maisel AS; Barrett-Connor E
Circulation; 2011 May; 123(19):2101-10. PubMed ID: 21536998
[TBL] [Abstract][Full Text] [Related]
29. Midregional proadrenomedullin and growth differentiation factor-15 are not influenced by obesity in heart failure patients.
Sinning C; Ojeda F; Wild PS; Schnabel RB; Schwarzl M; Ohdah S; Lackner KJ; Pfeiffer N; Michal M; Blettner M; Munzel T; Kempf T; Wollert KC; Kuulasmaa K; Blankenberg S; Salomaa V; Westermann D; Zeller T
Clin Res Cardiol; 2017 Jun; 106(6):401-410. PubMed ID: 28004184
[TBL] [Abstract][Full Text] [Related]
30. Prognostic Value of N-Terminal Pro-B-Type Natriuretic Peptide Levels in Heart Failure Patients With and Without Atrial Fibrillation.
Kristensen SL; Jhund PS; Mogensen UM; Rørth R; Abraham WT; Desai A; Dickstein K; Rouleau JL; Zile MR; Swedberg K; Packer M; Solomon SD; Køber L; McMurray JJV;
Circ Heart Fail; 2017 Oct; 10(10):. PubMed ID: 29018174
[TBL] [Abstract][Full Text] [Related]
31. Combined use of the novel biomarkers high-sensitivity troponin T and ST2 for heart failure risk stratification vs conventional assessment.
Lupón J; de Antonio M; Galán A; Vila J; Zamora E; Urrutia A; Bayes-Genis A
Mayo Clin Proc; 2013 Mar; 88(3):234-43. PubMed ID: 23384388
[TBL] [Abstract][Full Text] [Related]
32. Biomarkers and low risk in heart failure. Data from COACH and TRIUMPH.
Meijers WC; de Boer RA; van Veldhuisen DJ; Jaarsma T; Hillege HL; Maisel AS; Di Somma S; Voors AA; Peacock WF
Eur J Heart Fail; 2015 Dec; 17(12):1271-82. PubMed ID: 26466857
[TBL] [Abstract][Full Text] [Related]
33. Multimarker approach including CRP, sST2 and GDF-15 for prognostic stratification in stable heart failure.
Kuster N; Huet F; Dupuy AM; Akodad M; Battistella P; Agullo A; Leclercq F; Kalmanovich E; Meilhac A; Aguilhon S; Cristol JP; Roubille F
ESC Heart Fail; 2020 Oct; 7(5):2230-2239. PubMed ID: 32649062
[TBL] [Abstract][Full Text] [Related]
34. A Rising Star of the Multimarker Panel: Growth Differentiation Factor-15 Levels Are an Independent Predictor of Mortality in Acute Heart Failure Patients Admitted to an Emergency Clinical Hospital from Eastern Europe.
Miftode RS; Constantinescu D; Cianga CM; Petris AO; Costache II; Mitu O; Miftode IL; Mitu I; Timpau AS; Duca ST; Costache AD; Cianga P; Serban IL
Life (Basel); 2022 Nov; 12(12):. PubMed ID: 36556311
[TBL] [Abstract][Full Text] [Related]
35. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial.
Anand IS; Rector TS; Cleland JG; Kuskowski M; McKelvie RS; Persson H; McMurray JJ; Zile MR; Komajda M; Massie BM; Carson PE
Circ Heart Fail; 2011 Sep; 4(5):569-77. PubMed ID: 21715583
[TBL] [Abstract][Full Text] [Related]
36. Association of NT-proBNP and GDF-15 with markers of a prothrombotic state in patients with atrial fibrillation off anticoagulation.
Matusik PT; Małecka B; Lelakowski J; Undas A
Clin Res Cardiol; 2020 Apr; 109(4):426-434. PubMed ID: 31280356
[TBL] [Abstract][Full Text] [Related]
37. Biomarkers and diagnostics in heart failure.
Gaggin HK; Januzzi JL
Biochim Biophys Acta; 2013 Dec; 1832(12):2442-50. PubMed ID: 23313577
[TBL] [Abstract][Full Text] [Related]
38. Red cell distribution width outperforms other potential circulating biomarkers in predicting survival in idiopathic pulmonary arterial hypertension.
Rhodes CJ; Wharton J; Howard LS; Gibbs JS; Wilkins MR
Heart; 2011 Jul; 97(13):1054-60. PubMed ID: 21558476
[TBL] [Abstract][Full Text] [Related]
39. Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3.
Bayes-Genis A; de Antonio M; Vila J; Peñafiel J; Galán A; Barallat J; Zamora E; Urrutia A; Lupón J
J Am Coll Cardiol; 2014 Jan; 63(2):158-66. PubMed ID: 24076531
[TBL] [Abstract][Full Text] [Related]
40. Prognostic Value of Combined Biomarkers in Patients With Heart Failure: The Heartmarker Score.
van der Stam JA; Bouwmeester S; van Loon SLM; van Riel NAW; Dekker LR; Boer AK; Houthuizen P; Scharnhorst V
Ann Lab Med; 2023 May; 43(3):253-262. PubMed ID: 36544337
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
